NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. November 20 marks World COPD Day 2024, a worldwide ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

Mona Bafadhel receives funding from the National Institute of Health Research, Asthma+Lung UK, and Horizon Europe. For this study, Mona Bafadhel received funding from AstraZeneca to complete the study ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...

Understand the evolving practices in antimicrobial therapy, emphasizing shorter antibiotics without compromising outcomes.